A Path Opens for Gut-Focused Treatment in Younger IBD Patients
Inflammatory bowel disease, which includes both ulcerative colitis and Crohn's disease, isn't only an adult condition. Young children can and do develop these diseases, and treating them presents a particular challenge: many effective biologic drugs work by broadly suppressing the immune system, which carries real risks for a child's developing body, including increased infection risk. A treatment that works specifically within the gut, rather than dampening immune function everywhere, is generally considered a gentler option, but until recently, those gut-selective options simply weren't approved for very young children.
Takeda announced on June 9, 2026, that the FDA has accepted its application to expand the approved use of intravenous Entyvio (vedolizumab) to children as young as 2 years old with moderate-to-severe ulcerative colitis or Crohn's disease. Vedolizumab works by blocking a specific molecule that certain immune cells use to travel into gut tissue, which is why it's described as gut-selective, it largely keeps its effect localized to the digestive system rather than suppressing immune function throughout the entire body the way many other biologics do.
If the FDA ultimately approves this expanded use, Entyvio would become the only gut-selective biologic available to children as young as 2 with these conditions. Right now, families of very young children with IBD often face a difficult choice between using an approved biologic off-label, meaning outside its official approved age range, or relying on more broadly immunosuppressive medications that carry a different risk profile. Having an on-label, gut-selective option specifically studied and approved for this age group would close a real gap in pediatric IBD care.
The FDA's acceptance of the application means the agency will now formally review the data Takeda has submitted, which typically takes several months to a year before a final decision. This is a regulatory process step, not yet an approval, so the expanded pediatric indication isn't available yet. But for families managing IBD in a very young child, an application acceptance like this is a meaningful signal that a gentler, more targeted treatment option could realistically become available within the next year or so.
If your child has been diagnosed with ulcerative colitis or Crohn's disease at a young age, this is worth discussing with your pediatric gastroenterologist, both to understand your current options and to keep an eye on when this expanded approval might come through. It's also a reasonable moment to ask whether an early, gut-selective option might be appropriate once it clears review, rather than defaulting straight to a more broadly immunosuppressive medication.